Skip to main content
Clinical Trials/NCT06182059
NCT06182059RecruitingNot Applicable

Enhanced Recovery After Surgery and Total Knee Replacement: A Prospective, Randomized Study on the Rule of Peripheral Nerve Blocks on Persistent Postoperative Pain Six Months After Surgery

Policlinico di Monza SpA2 sites in 1 country436 target enrollmentStarted: January 12, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
436
Locations
2
Primary Endpoint
Persistent post surgical pain

Study Overview

Brief Summary

Patients undergone total knee replacement are randomized to receive a "fast track" regional anesthesia protocol or a "traditional" regional anesthesia continuous infusion by both a femoral and sciatic catheter to assess if this latter technique may reduce persistent postoperative pain six months after surgery

Detailed Description

Patients undergone to primary total knee replacement with spinal anesthesia are randomized to receive a continuous adductor canal block infusion + an ipack block or a continuous femoral nerve block + a continuous sciatic nerve block just at the end of surgery. Both group will receive a multimodal analgesia with paracetamol, ketorolac, desametasone and morphine as a rescue.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • primary total knee replacement with a written informed consent

Exclusion Criteria

  • Allergy to local anesthetics or any drugs involve in the study
  • Controindication to regional anesthesia
  • chronic use of opioids
  • BMI > 35 kg m2

Outcomes

Primary Outcomes

Persistent post surgical pain

Time Frame: 0-6-month

Numeric rating score (0-10) over 4 at the follow up 6-month after total knee replacement

Secondary Outcomes

  • acute postoperative pain(0-72 hours)
  • Morphine requirement(0-72 hours)

Investigators

Sponsor
Policlinico di Monza SpA
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Gianluca Cappelleri

MD

Policlinico di Monza SpA

Study Sites (2)

Loading locations...

Similar Trials